Introduction
============

Gram-negative bacteria are among the most common causes of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).[@b1-idr-11-783]--[@b3-idr-11-783] Among them, *Pseudomonas aeruginosa* is often the most common pathogen isolated, followed by Enterobacteriaceae including *Escherichia coli* and *Klebsiella pneumoniae*.[@b4-idr-11-783] Although less common, HAP and VAP caused by *Acinetobacter baumannii* is among the most challenging Gram-negatives to treat due to high virulence, increasing resistance, and few available antibiotics with activity.[@b4-idr-11-783],[@b5-idr-11-783] Collectively, these organisms account for nearly three quarters of HAP and VAP cases.[@b6-idr-11-783]

The World Health Organization (WHO) lists antibiotic resistance as one of the most significant threats to global health, food security, and development today.[@b7-idr-11-783] While Gram-negative resistance is a concern worldwide, certain countries have rates well above the average. Multidrug resistance in the Asia-Pacific region has risen at an alarming pace, with few new antimicrobials available to address this increase.[@b8-idr-11-783] New antibiotics or novel technology to improve administration of available antibiotics are needed to address resistant organisms in HAP and VAP in the Asia-Pacific countries.

Amikacin Inhale (BAY41-6551, Bayer Pharma AG, Berlin, Germany) is a reformulated solution of amikacin combined with an inhalational drug delivery system that is currently in Phase III development as an adjunctive therapy for the treatment of Gram-negative pneumonia in intubated and mechanically ventilated patients with HAP or VAP.[@b9-idr-11-783] When administered twice daily through the proprietary Pulmonary Drug Delivery System (PDDS), amikacin concentrations in the tracheal aspirates of mechanically ventilated patients were ≥ 6,400 mg/L (25 × 256 mg/L) in 50% of patients. Simulation of these exposures in the in vitro pharmacodynamic model showed bactericidal activity against most multidrug-resistant (MDR) *K. pneumoniae* and *P. aeruginosa* tested with amikacin minimum inhibitory concentrations (MICs) ≤ 256 mg/L.[@b10-idr-11-783] Herein, the in vitro potency of amikacin was assessed using Clinical and Laboratory Standards Institute (CLSI) and inhalation-based breakpoints against *E. coli*, *K. pneumoniae*, *P. aeruginosa*, and *A. baumannii* derived from Chinese patients with infection sources (ie, blood and respiratory tract) typically yielding pathogens in HAP/VAP infection.

Materials and methods
=====================

Participating sites
-------------------

Fourteen hospitals geographically dispersed throughout China provided clinical non-duplicate blood and respiratory isolates of *E. coli*, *K. pneumoniae*, *P. aeruginosa*, and *A. baumannii* that were collected between December 23, 2015, and December 30, 2016. Organisms were identified at each participating center using standard methods and shipped to the central laboratory (Peking University People's Hospital, Beijing, China) for determination of MICs. The study was reviewed and approved by the Ethical Committees at Peking University People's Hospital and Hartford Hospital (Hartford, CT, USA). The Ethical Committees waived the need for informed consent as no private health information was collected.

Antibiotic susceptibility testing
---------------------------------

Antibiotic MICs were determined for each isolate by agar dilution at the central lab according to CLSI guidelines (M07-A9).[@b11-idr-11-783] The antimicrobials tested included meropenem (Sumitomo Pharmaceuticals Co., Osaka, Japan), imipenem (Sigma-Aldrich Co., St Louis, MO, USA), ertapenem (Sigma-Aldrich), ceftazidime (Sigma-Aldrich), cefotaxime (Sigma-Aldrich), ceftriaxone (Sigma-Aldrich), cefepime (Sigma-Aldrich), piperacillin/tazobactam (TZP) (Wyeth Pharmaceuticals, Collegeville, PA, USA), cefotaxime/clavulanic acid (Sigma-Aldrich), cefoxitin (Sigma-Aldrich), amikacin (Sigma-Aldrich), ceftazidime/clavulanic acid (Sigma-Aldrich), ciprofloxacin (Bayer AG, Leverkusen, Germany), levofloxacin (Bayer AG), minocycline (Sigma-Aldrich), polymyxin B (Sigma-Aldrich), and tigecycline (Wyeth Pharmaceuticals). The procedures for each set of tests were validated by determining the MICs for reference strains (*P. aeruginosa* ATCC 27853, *E. coli* ATCC 25922, and *E. coli* ATCC 35218), as recommended by CLSI.[@b12-idr-11-783] The MIC~50~, MIC~90~, range, and percent susceptibility were calculated based on CLSI or US Food and Drug Administration (FDA) (for tigecycline only) susceptibility breakpoints.[@b12-idr-11-783] Amikacin susceptibility was also assessed using a pharmacodynamic-based threshold MIC of ≤ 256 mg/L, which was derived from the in vitro pharmacodynamic model against *K. pneumoniae* and *P. aeruginosa*. When simulated at concentrations achievable in the epithelial lining fluid of patients receiving Amikacin Inhale (BAY41-6551), bactericidal activity was observed against isolates with MICs ≤ 256 mg/L.[@b10-idr-11-783]

*E. coli* and *K. pneumoniae* were tested for extended-spectrum beta-lactamases (ESBL) production if they had an MIC of ≥ 1 mg/L against ceftazidime or cefotaxime. CLSI defined ESBL confirmation studies were undertaken using additional MIC testing of ceftazidime with clavulanic acid and cefotaxime with clavulanic acid. Enterobacteriaceae testing non-susceptible to ertapenem, meropenem, or imipenem were defined as carbapenem-resistant Enterobacteriaceae (CRE). Non-fermenters testing non-susceptible to meropenem or imipenem were defined as carbapenem-resistant *P. aeruginosa* (CRPA) or *A. baumannii* (CRAB), respectively.

The potency of amikacin was further assessed in organisms meeting the definition of MDR.[@b13-idr-11-783] For the Enterobacteriaceae, MDR was defined as an isolate non-susceptible to one agent in at least three of the following antimicrobial categories: aminoglycosides, piperacillin/tazobactam, carbapenems, 3rd or 4th generation cephalosporins, fluoroquinolones, glycylcyclines, polymyxins, or tetracyclines. For the *P. aeruginosa*, MDR was defined as an isolate non-susceptible to one agent in at least three of the following antimicrobial categories: aminoglycosides, piperacillin/tazobactam, group 2 carbapenems, anti-pseudomonal cephalosporins, fluoroquinolones, or polymyxins. For *A. baumannii*, MDR was defined as an isolate non-susceptible to one agent in at least three of the following antimicrobial categories: aminoglycosides, piperacillin/tazobactam, group 2 carbapenems, extended-spectrum cephalosporins, fluoroquinolones, polymyxins, or tetracyclines.

Results
=======

Isolate numbers and patient characteristics
-------------------------------------------

A total of 523 blood or respiratory isolates were tested as follows: *E. coli* (n = 151; all blood), *K. pneumoniae* (n = 129; blood, n = 120; respiratory, n = 9), *P. aeruginosa* (n = 112; blood, n = 57; respiratory, n = 55), and *A. baumannii* (n = 131; blood, n = 89; respiratory, n = 42). Patients contributing these samples were 58 ± 19 (range: 1--97) years old, and 207 (39.6%) were female.

### E. coli and K. pneumoniae

Results for the *E. coli* and *K. pneumoniae* are provided in [Table 1](#t1-idr-11-783){ref-type="table"}. Against *E. coli*, the most active antibiotics based on percent susceptibility included tigecycline (100% susceptible), the carbapenems (meropenem, imipenem, and ertapenem: 96.0%--98.0% susceptible), and amikacin (94.7% susceptible); 95.4% of *E. coli* had an MIC ≤ 256 mg/L. Polymyxin B also had potent activity against *E. coli*, but no CLSI or FDA breakpoints are currently identified for this agent. The ESBL rate among these *E. coli* was 86/188 (45.7%). Tigecycline, carbapenems, piperacillin/tazobactam, and amikacin retained susceptibility in the 90th percentile for ESBL-producing *E. coli*. Forty-four (29.1%) *E. coli* met the definition for an MDR organism. Amikacin MIC~50~/MIC~90~ and percent susceptibility in these MDR organisms was 2/\>256 mg/L and 81.8%, respectively; 84.1% of *E. coli* had an MIC ≤ 256 mg/L.

Against *K. pneumoniae*, the greatest susceptibility was observed for tigecycline (96.0%) followed by amikacin (83.7%), meropenem (82.2%), and ertapenem (80.6%). Polymyxin B displayed potent MICs as well similar to those against *E. coli*. The ESBL rate among these *K. pneumoniae* was 45/186 (24.2%). Only tigecycline susceptibility remained high at 95.6%, whereas amikacin declined to 71.1%. Carbapenems remained active against 77.8%--80.0% of ESBL-producing *K. pneumoniae*. Forty-four (34.1%) *K. pneumoniae* met the definition for an MDR organism. Amikacin MIC~50~/MIC~90~ and percent susceptibility in these MDR organisms was 2/\>256 mg/L and 63.6% (using both break-point and pharmacodynamic MIC threshold), respectively.

CRE was observed in 4.0% and 20.9% of *E. coli* and *K. pneumoniae* populations, respectively. Among the 33 CRE isolates, tigecycline provided the greatest susceptibility at 90.0%, followed by amikacin at 69.7% (using both thresholds). The polymxin B MIC~50~/MIC~90~ was 0.25/0.25 mg/L. All other tested antibiotics portrayed susceptibility less than 30.3%.

### P. aeruginosa and A. baumannii

*P. aeruginosa* and *A. baumannii* MIC and susceptibility results are provided in [Table 2](#t2-idr-11-783){ref-type="table"}. Polymyxin B was the most active antibiotic against *P. aeruginosa* with an observed susceptibility of 100%, followed by amikacin at 91.1%, ciprofloxacin (83.9%), levofloxacin (81.3%), ceftazidime (81.3%), and cefepime (80.4%). Notably, carbapenem resistance was common in China with 47/112 (42%) isolates displaying non-susceptibility to either meropenem or imipenem. Among CRPA, polymyxin B susceptibility remained at 100%, while amikacin declined to 80.9%. Eighty-three percent of CRPA would be inhibited at ≤256 mg/L. Twenty-two (19.6%) *P. aeruginosa* met the definition for an MDR organism. Amikacin MIC~50~/MIC~90~ and percent susceptibility in these MDR organisms was 8/\>256 mg/L and 54.5%, respectively; 59.1% of *P. aeruginosa* had an MIC ≤ 256 mg/L.

For *A. baumannii*, the most active antibiotic was polymyxin B (99.2% susceptible) followed by minocycline (61.8%). Tigecycline displayed MICs that were 1--2 dilutions lower than minocycline, but no breakpoint is yet available for interpretation. Amikacin susceptibility was 30.5%, while susceptibility to the tested β-lactams and fluoroquinolones were less than 20%. CRAB was observed in the majority \[111/131 (84.7%)\] of isolates. Among CRAB, only polymyxin B retained reliable susceptibility at 99.1%. Amikacin susceptibility declined to 18.0%. Essentially all CRAB isolates (n = 110) met the definition for an MDR organism, with amikacin percent susceptibility at 17.3%; 18.2% of *A. baumannii* had an MIC ≤ 256 mg/L.

Discussion
==========

Amikacin Inhale provides a novel inhalation adjuvant therapy for the treatment of HAP and VAP by combining the potent in vitro activity of amikacin against Gram-negative bacteria and high concentrations achieved in the lower airways when administered via the proprietary PDDS.[@b9-idr-11-783] In vitro pharmacodynamics studies have observed antibacterial activity up to and including MICs as high as 256 mg/L, four times the CLSI breakpoint.[@b10-idr-11-783] The aim of this study was to compare the in vitro potency of amikacin with that of other intravenous antibiotics in China. We demonstrated widespread antimicrobial resistance in China among four common Gram-negative bacteria isolated from blood and respiratory tract samples. Notably, amikacin displayed good in vitro activity against most *E. coli*, *K. pneumoniae*, and *P. aeruginosa*. In contrast, few antimicrobials had activity against the contemporary *A. baumannii* collected in China.

More than 90% of *E. coli* strains collected in this study were susceptible to amikacin, tigecycline, piperacillin/tazobactam, and the carbapenems. The 2015 Tigecycline Evaluation and Surveillance Trial (TEST) from the Asia-Pacific region observed similar susceptibility rates for these antibiotics with rates above 90%.[@b8-idr-11-783] Amikacin susceptibility was specifically 98.1% in TEST versus 94.7% here. In contrast, ESBL rates among *E. coli* in these Chinese hospitals were more than twice that observed in the Asia-Pacific region as a whole (45.7% vs 21.6%). As a result, cephalosporin and fluoroquinolone susceptibility were observed to be lower herein. Among the ESBL-producing *E. coli*, amikacin, tigecycline, piperacillin/tazobactam, and the carbapenems retained excellent susceptibility rates, which is also congruent with TEST. It should be noted that polymyxin B MIC~50~ and MIC~90~ for these isolates were 0.125 and 0.25 mg/L, respectively. Although CLSI or FDA interpretative criteria for the polymyxins are not currently available for Enterobacteriaceae, MICs are well below the susceptibility breakpoints established for non-fermenting Gram-negative bacteria[@b12-idr-11-783] and that of the colistin breakpoint (≤2 mg/L) for Enterobacteriaceae set by the European Committee on Antimicrobial Susceptibility Testing (EUCAST).[@b14-idr-11-783] While these in vitro data in and of themselves suggest that this antibiotic class may have a clinical role, it must be remembered that these antibacterials poorly penetrate the lung after intravenous administration thus their utility as monotherapy agents is severely limited in bronchopulmonary infection.

Against *K. pneumoniae* isolates, only tigecycline was observed to have susceptibilities above 90% in China, whereas amikacin, meropenen, and ertapenem demonstrated susceptibilities between 80.6% and 83.7%. These results again resemble observations from TEST from the Asia-Pacific region.[@b8-idr-11-783] The ESBL rate among *K. pneumoniae* in China was 24.2% compared with 23.8% from the Asia-Pacific region as a whole; however, a closer evaluation of *K. pneumoniae* from China during 2004--2010 found a much higher ESBL rate of 63.6%. In contrast to the sustained susceptibility above 90% reported in TEST, amikacin susceptibilities against these ESBL-producing *K. pneumoniae* declined to 71.1% in China. As observed with *E. coli*, polymyxin B MICs typically remained below 0.5 mg/L against these *K. pneumoniae* isolates.

CRE was determined phenotypically in this study with rates of 4.0% and 20.9% among these *E. coli* and *K. pneumoniae*, respectively. These CRE demonstrated high rates of MDR as demonstrated by only tigecycline (90.0%) and amikacin (69.7%) having susceptibilities greater than \~30%. For amikacin, all isolates found to be non-susceptible had MICs \>256 mg/L. The prevalence of the 16s rRNA methylase, the aminoglycoside modifying enzyme responsible for very high MICs (\> 512 mg/L), has been reported to be endemic in regions of East Asia, including China.[@b15-idr-11-783] This has potential clinical relevance since the Amikacin Inhale regimen has demonstrated antibacterial activity for isolates with MICs up to 256 mg/L, but not above this threshold. As a result of these high MICs among non-susceptible isolates, there was very little difference between amikacin susceptibility calculated using the CLSI breakpoint versus the in vitro model pharmacodynamic threshold. These observations in China are in contrast to ESBL-producing Enterobacteriaceae, for example, from the USA, in which 9% had MICs of 32 mg/L.[@b16-idr-11-783]

Polymyxin B and amikacin were the only tested antibiotics demonstrating susceptibility greater than 90% against *P. aeruginosa*. Amikacin susceptibility in China (91.1%) was similar to rates reported in the Asia-Pacific region during TEST. (92.5%), as well as in the USA (95%).[@b8-idr-11-783],[@b16-idr-11-783] Similar to the Enterobacteriaceae, few *P. aeruginosa* harbored amikacin MICs between 32 and 256 mg/L. Carbapenem resistance was common in *P. aeruginosa* (42.0%); against these isolates, amikacin susceptibility was 80.9%, and 83.0% of isolates were inhibited at 256 mg/L.

*A. baumannii* is a problematic isolate worldwide due to high levels of resistance secondary production of Class D carbapenemases, such as OXA-23, OXA-24 or -40, OXA-51, OXA-58, and OXA-143.[@b17-idr-11-783] The isolates collected herein were no different with carbapenem resistance apparent in 84.7% of the population and MDR present in 84.0%. The majority of tested antibiotics (carbapenems, cephalosporins, and fluoroquinolones) demonstrated susceptibility rates below 20%. Amikacin susceptibility was 30.5% and 17.3% for the total and MDR populations, respectively. Since the vast majority of the amikacin non-susceptible isolates by CLSI criteria had MICs \> 256 mg/L, utilization of the inhalation breakpoint did very little to improve the overall susceptibility profile of amikacin against this Chinese population of *A. baumannii*. Only polymyxin B retained excellent susceptibility rates (99.1%--99.2%), followed by minocycline (55.9%--61.8%). Of note, tigecycline MIC~50~/MIC~90~ was 2/4 mg/L, \~1--2 dilutions lower than minocycline; however, no interpretative susceptibility criteria are currently established for this agent. The rates of MDR *A. baumannii* were 48.5% in the Asia-Pacific region during the TEST surveillance study.[@b8-idr-11-783] Similar poor susceptibilities were noted for all tested antibiotics, including amikacin, in that study as well.

Notable limitations of the current study include too few isolates within each species to conduct hospital-specific or regional distributional analyses. CLSI recommends no fewer than 30 isolates for an accurate identification of susceptibility, and splitting the current isolate collections by the 14 hospitals or the six representative regions would fall below that threshold. Additionally, only isolates collected from blood and respiratory tract specimens were included, as these are clinically pertinent to antibiotic used for pneumonia. Therefore, the observed resistance rates may not be representative or rates at other sources such as urine or wound, for example.

Conclusions
===========

In summary, MDR resistance among *E. coli*, *K. pneumoniae*, *P. aeruginosa*, and *A. baumannii* is common in China. Amikacin displayed similar, if not better, susceptibility rates versus the majority of available antibiotics, particularly against the *E. coli*, *K. pneumoniae*, and *P. aeruginosa* populations. However, few antibiotics, with the exception of polymyxin B, are available to address the MDR rates of *A. baumannii*. This study provides valuable data on the potential utility of Amikacin Inhale against Gram-negative bacteria from blood and respiratory tract sources in China.

The following hospitals contributed isolates to this study: Peking University People's Hospital (Beijing, China); Peking Union Medical College Hospital (Beijing, China); Fujian Medical University First Affiliated Hospital (Fuzhou, China); Harbin Medical University First Affiliated Hospital (Harbin, China); The First Affiliated Hospital of Nanjing Medical University (Nanjing, China); Shanghai Ruijin Hospital (Shanghai, China); Tianjin Medical University General Hospital (Tianjin, China); Tongji Hospital in Wuhan (Wuhan, China); Xijing Hospital Affiliated to the Fourth Military Medical University (Xi'an, China); Xinjiang medical University First Affiliated Hospital (Urumchi, China); Sir Run Run Shaw Hospital (Hangzhou, China); First Affiliated Hospital of Zhengzhou University (Zhengzhou, China); First Affiliated Hospital of China Medical University (Shenyang, China); First Affiliated Hospital of Zhongshan Medical University (Guangzhou, China). This study was funded through an investigator initiated grant by Bayer Pharma AG (Berlin, Germany).
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###### 

MIC~50~, MIC~90~, range, and percent susceptibility for amikacin and comparators against *Escherichia coli* and *Klebsiella pneumoniae* isolates

  Isolates                                   Antimicrobial   MIC~50~(mg/L)   MIC~90~(mg/L)   Range (mg/L)                                     %S
  ------------------------------------------ --------------- --------------- --------------- ------------------------------------------------ -------------------------------------------------------
  *E. coli*, all isolates (n = 188)          Amikacin        2               4               1--\>256                                         94.7 (95.4)[a](#tfn1-idr-11-783){ref-type="table-fn"}
  Cefoxitin                                  8               64              2--\>256        62.9                                             
  Cefepime                                   2               32              ≤0.016--\>256   53.6                                             
  Ceftazidime                                2               64              0.064--\>256    64.9                                             
  Cefotaxime                                 16              256             0.032--\>256    32.5                                             
  Ceftriaxone                                32              256             0.032--\>256    32.5                                             
  Ciprofloxacin                              16              \>64            ≤0.016--\>64    34.4                                             
  Ertapenem                                  0.032           0.25            ≤0.016--\>64    96.0                                             
  Imipenem                                   0.125           0.25            ≤0.016--16      98.0                                             
  Levofloxacin                               8               \>64            ≤0.016--\>64    37.1                                             
  Meropenem                                  ≤0.016          0.032           ≤0.016--\>32    98.0                                             
  Minocycline                                2               16              0.5--128        72.8                                             
  Piperacillin/tazobactam                    2               8               0.5--\>256      92.1                                             
  Polymyxin B                                0.125           0.25            0.064--8        NA[b](#tfn2-idr-11-783){ref-type="table-fn"}     
  Tigecycline                                0.25            0.5             0.125--2        100[c](#tfn3-idr-11-783){ref-type="table-fn"}    
  *E. coli*, ESBL producing (n = 86)         Amikacin        2               8               1--\>256                                         93.0 (94.2)[a](#tfn1-idr-11-783){ref-type="table-fn"}
  Cefoxitin                                  8               32              2--\>256        60.5                                             
  Cefepime                                   8               32              0.032--\>256    25.6                                             
  Ceftazidime                                4               64              0.125--\>256    54.7                                             
  Cefotaxime                                 64              256             2--\>256        0.0                                              
  Ceftriaxone                                64              256             4--\>256        0.0                                              
  Ciprofloxacin                              32              \>64            ≤0.016--\>64    20.9                                             
  Ertapenem                                  0.032           0.25            ≤0.016--2       98.8                                             
  Imipenem                                   0.125           0.25            ≤0.016--0.5     100                                              
  Levofloxacin                               16              \>64            ≤0.016--\>64    25.6                                             
  Meropenem                                  ≤0.016          0.032           ≤0.016--0.125   100                                              
  Minocycline                                2               16              0.5--128        68.6                                             
  Piperacillin/tazobactam                    2               4               0.5--64         96.5                                             
  Polymyxin B                                0.125           0.25            0.064--8        NA[b](#tfn2-idr-11-783){ref-type="table-fn"}     
  Tigecycline                                0.25            0.5             0.125--2        100[c](#tfn3-idr-11-783){ref-type="table-fn"}    
  *K. pneumoniae*, all isolates (n = 186)    Amikacin        1               \>256           0.5--\>256                                       83.7 (83.7)[a](#tfn1-idr-11-783){ref-type="table-fn"}
  Cefoxitin                                  4               \>256           1--\>256        65.9                                             
  Cefepime                                   0.25            64              ≤0.016--\>256   61.2                                             
  Ceftazidime                                0.5             128             0.032--\>256    66.7                                             
  Cefotaxime                                 0.5             256             ≤0.016--\>256   52.7                                             
  Ceftriaxone                                0.5             256             ≤0.016--\>256   51.2                                             
  Ciprofloxacin                              0.25            \>64            ≤0.016--\>64    64.3                                             
  Ertapenem                                  ≤0.016          32              ≤0.016--\>32    80.6                                             
  Imipenem                                   0.25            16              ≤0.016--\>32    79.8                                             
  Levofloxacin                               0.25            32              ≤0.016--\>64    69.0                                             
  Meropenem                                  0.032           32              ≤0.016--\>32    82.2                                             
  Minocycline                                4               32              0.5--256        54.3                                             
  Piperacillin/tazobactam                    4               \>256           ≤0.016--\>256   76.7                                             
  Polymyxin B                                0.25            0.5             0.064--4        NA[b](#tfn2-idr-11-783){ref-type="table-fn"}     
  Tigecycline                                1               2               ≤0.016--8       96.1[c](#tfn3-idr-11-783){ref-type="table-fn"}   
  *K. pneumoniae*, ESBL producing (n = 45)   Amikacin        1               \>256           0.5--\>256                                       71.1 (71.1)[a](#tfn1-idr-11-783){ref-type="table-fn"}
  Cefoxitin                                  8               256             2--\>256        60.0                                             
  Cefepime                                   8               32              1--64           20.0                                             
  Ceftazidime                                16              64              0.25--\>256     37.8                                             
  Cefotaxime                                 64              256             4--\>256        0.0                                              
  Ceftriaxone                                64              256             8--\>256        0.0                                              
  Ciprofloxacin                              16              \>64            0.032--\>64     35.6                                             
  Ertapenem                                  0.125           32              ≤0.016--\>32    77.8                                             
  Imipenem                                   0.25            16              ≤0.016--\>32    77.8                                             
  Levofloxacin                               4               64              0.032--\>64     44.4                                             
  Meropenem                                  0.032           8               ≤0.016--\>32    80.0                                             
  Minocycline                                8               64              0.5--128        26.7                                             
  Piperacillin/tazobactam                    4               \>256           0.5--\>256      71.1                                             
  Polymyxin B                                0.25            0.25            0.064--4        NA[b](#tfn2-idr-11-783){ref-type="table-fn"}     
  Tigecycline                                1               2               0.125--8        95.6[c](#tfn3-idr-11-783){ref-type="table-fn"}   

**Notes:**

Amikacin percent susceptibility calculated using the CLSI breakpoint of ≤ 16 mg/L (PD threshold concentration: ≤ 256 mg/L).

Polymyxin B susceptibility breakpoints are not established by CLSI or the FDA.

Tigecycline percent susceptibility calculated using the FDA breakpoint of ≤ 2 mg/L.

**Abbreviations:** MIC, minimum inhibitory concentration; %S, percentage susceptibility; ESBL, extended-spectrum beta-lactamase; CLSI, Clinical and Laboratory Standards Institute; FDA, US Food and Drug Administration; PD, pharmacodynamic.

###### 

MIC~50~, MIC~90~, range, and percent susceptibility for amikacin and comparators against *Pseudomonas aeruginosa* and *Acinetobacter baumannii*

  Isolates                                  Antimicrobial   MIC~50~(mg/L)   MIC~90~(mg/L)   Range (mg/L)                                   %S
  ----------------------------------------- --------------- --------------- --------------- ---------------------------------------------- -------------------------------------------------------
  *P. aeruginosa*, all isolates (n = 112)   Amikacin        2               8               ≤0.016--\>256                                  91.1 (92.0)[a](#tfn5-idr-11-783){ref-type="table-fn"}
  Cefepime                                  2               16              ≤0.016--256     80.4                                           
  Ceftazidime                               2               64              ≤0.016--\>256   81.3                                           
  Ciprofloxacin                             0.125           4               0.032--\>64     83.9                                           
  Imipenem                                  2               32              ≤0.016--\>32    59.8                                           
  Levofloxacin                              0.5             8               ≤0.016--\>64    81.3                                           
  Meropenem                                 0.5             16              ≤0.016--\>32    68.8                                           
  Piperacillin/tazobactam                   4               128             ≤0.016--\>256   79.5                                           
  Polymyxin B                               0.5             1               0.032--2        100                                            
  *P. aeruginosa*, CRPA (n = 47)            Amikacin        2               \>256           0.5--\>256                                     80.9 (83.0)[a](#tfn5-idr-11-783){ref-type="table-fn"}
  Cefepime                                  8               64              1--256          59.6                                           
  Ceftazidime                               4               256             0.5--\>256      66.0                                           
  Ciprofloxacin                             0.5             32              0.064--\>64     68.1                                           
  Imipenem                                  16              \>32            2--\>32         4.3                                            
  Levofloxacin                              2               32              0.125--\>64     63.8                                           
  Meropenem                                 8               \>32            0.25--\>32      25.5                                           
  Piperacillin/tazobactam                   16              256             0.25--\>256     59.6                                           
  Polymyxin B                               0.5             1               0.25--2         100                                            
  *A. baumannii*, all isolates (n = 131)    Amikacin        \>256           \>256           1--\>256                                       30.5 (31.3)[a](#tfn5-idr-11-783){ref-type="table-fn"}
  Cefepime                                  64              128             0.032--256      16.0                                           
  Ceftazidime                               128             \>256           0.125--\>256    18.3                                           
  Ciprofloxacin                             64              \>64            ≤0.016--\>64    18.3                                           
  Imipenem                                  \>32            \>32            0.25--\>32      15.3                                           
  Levofloxacin                              8               16              0.032--32       19.1                                           
  Meropenem                                 32              \>32            0.032--\>32     15.3                                           
  Minocycline                               4               16              0.032--256      61.8                                           
  Piperacillin/tazobactam                   \>256           \>256           ≤0.016--\>256   14.5                                           
  Polymyxin B                               0.25            0.5             0.125--\>32     99.2                                           
  Tigecycline                               2               4               0.064--32       NA[b](#tfn6-idr-11-783){ref-type="table-fn"}   
  *A. baumannii*, CRAB (n = 111)            Amikacin        \>256           \>256           2--\>256                                       18.0 (18.0)[b](#tfn5-idr-11-783){ref-type="table-fn"}
  Cefepime                                  64              128             2--256          0.9                                            
  Ceftazidime                               128             \>256           4--\>256        3.6                                            
  Ciprofloxacin                             64              \>64            0.064--\>64     3.6                                            
  Imipenem                                  \>32            \>32            8--\>32         0                                              
  Levofloxacin                              8               16              0.064--32       4.5                                            
  Meropenem                                 32              \>32            8--\>32         0                                              
  Minocycline                               4               16              0.064--256      55.9                                           
  Piperacillin/tazobactam                   \>256           \>256           64--\>256       0                                              
  Polymyxin B                               0.25            0.5             0.125--\>32     99.1                                           
  Tigecycline                               2               4               0.125--32       NA[b](#tfn6-idr-11-783){ref-type="table-fn"}   

**Notes:**

Amikacin percent susceptibility calculated using the CLSI breakpoint of ≤ 16 mg/L (PD threshold concentration: ≤ 256 mg/L).

Tigecycline susceptibility breakpoints are not established by CLSI or the FDA.

**Abbreviations:** MIC, minimum inhibitory concentration; %S, percentage susceptibility; CRPA, carbapenem-resistant *P. aeruginosa*; CRAB, carbapenem-resistant *A. baumannii*; CLSI, Clinical and Laboratory Standards Institute; FDA, US Food and Drug Administration; PD, pharmacodynamic.
